Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide (NCT01729260) (2021)

Government Record · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (sponsor) · May 7, 2021

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (sponsor), 2021-05-07: The Johns Hopkins phase I trial that carried the preclinical finding into patients: mebendazole added to temozolomide in newly diagnosed high-grade glioma, 24 participants, started 4 April 2013, completed 16 April 2021. ClinicalTrials.gov holds no posted results for it.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (sponsor), 2021-05-07: The Johns Hopkins phase I trial that carried the preclinical finding into patients: mebendazole added to temozolomide in newly diagnosed high-grade glioma, 24 participants, started 4 April 2013, completed 16 April 2021. ClinicalTrials.gov holds no posted results for it. Registry entry, opened and read through the ClinicalTrials.gov API v2 on 2026-11-19. Registered, no results posted – the reason for PARTLY SUPPORTS. Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; phase 1; enrollment 24; status COMPLETED; primary completion 2021-04-16; last update posted 2021-05-07; results section absent. This is the trial referred to in the 2015 Bai paper as 'a Phase I clinical trial with a dose escalation of MBZ for newly diagnosed high-grade glioma patients has been initiated (NCT01729260)'. Related: NCT02644291 (paediatric recurrent brain tumours, N=16, completed 2022, no results posted); NCT03628079 (Repos Pharma, GI cancer, N=11, TERMINATED 2019); NCT03925662 (mebendazole as adjuvant in colon cancer, Egypt, recruiting, N=40). Also filed as MBC-01, MBD-14 (claims C1, C3, C7).